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Abstract
Background Multi-component vocational rehabilitation (VR)
provides positive short-term outcomes in patients with pro-
longed fatigue.
Purpose The purpose of this study is to evaluate the long-
term outcomes ofDutchmulti-component VR up to 18months
after treatment.
Method In a pre–post-study, measurements were taken before
treatment (t0), after treatment (t1) and in long-term follow-ups
at 6 (t2), 12 (t3) and 18 months (t4) after treatment. Primary
outcomes (fatigue, work participation and workability) and
secondary outcomes [physical and social functioning, mental
health and heart rate variability (HRV)] were assessed over
time using linear mixed models analyses. Post hoc long-term
outcomes were compared with t0 and t1.
Results Sixty patients with severe fatigue complaints partic-
ipated. The primary outcomes significantly (p<0.001) im-
proved at follow-ups compared with t0 and showed no
relapse compared with t1. Moreover, fatigue decreased
(p<0.002) whereas workability (p<0.001) and work partic-
ipation (p<0.001) increased further after treatment (t1). The
secondary outcomes, physical functioning, mental health, so-
cial functioning and HRV, improved significantly (p<0.001,
p<0.001, p<0.001 and p00.049, respectively) over the long
term compared with t0. At 6-month follow-up (t2), mental
health (p<0.003) and social functioning (p00.003) further
increased after the treatment was stopped.
Conclusion Multi-component VR treatments seem to sig-
nificantly and in a clinically relevant way decrease fatigue
symptoms and improve individual functioning and work
participation in patients with severe prolonged fatigue over
the long term and without showing relapse.
Keywords Biopsychosocial intervention .Multi-component
treatment . Practice-based research . Prolonged fatigue
complaints . Return to work .Work-directed intervention
Introduction
Prolonged fatigue is highly prevalent in the general popula-
tion [1, 2] and is also a prominent symptom in chronic
diseases such as rheumatoid arthritis [3], cancer [4] and
depressive disorders [5]. In addition, fatigue can be a dis-
crete disorder (i.e. chronic fatigue syndrome (CFS)) [6] or
occur independent of a specific chronic disease or disorder
(i.e. common health problem) [7]. In all cases, in addition to
individual suffering, prolonged fatigue can affect social and
occupational functioning that may result in negative conse-
quences concerning work capacity. Sickness absence due to
prolonged fatigue may result in poor quality of life [8] and
serious economic consequences [9]. If effective treatments
for workers who are disabled from prolonged fatigue were
available, work participation and health could be improved.
Because of its multifactorial origin, the biopsychosocial
model [10], which states that sickness and health result from
a complex interaction between biological, psychological and
social factors, seems appropriate to explain prolonged fa-
tigue [11, 12]. In line with this model, mechanisms respon-
sible for the perpetual nature of prolonged fatigue have been
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investigated. From a biological perspective, prolonged fa-
tigue is related to dysregulation of physiological stress sys-
tems due to overuse of these systems [11, 13, 14]. In
addition, cognitive and behavioural factors (e.g. causal at-
tribution, low self-efficacy, dysfunctional beliefs about ac-
tivity and fatigue) are also involved in the perpetuation of
fatigue complaints [15–17]. Furthermore, lack of social
support can be a perpetuating factor in fatigued patients
[18]. To stimulate effective recovery in fatigued patients,
treatments should take individual perpetuating factors into
account [19, 20]. In the Netherlands, outpatient vocational
rehabilitation (VR) institutions guide workers with pro-
longed fatigue and functional limitations. These institutions
use multi-component treatments to increase physical and
mental functioning, and facilitate work participation. These
real-life practices have been evaluated before, using process
and outcome measures in a population of disabled fatigued
patients recruited from the practice setting [21]. This kind of
research can be identified as practice-based research and is
suitable for evaluating multi-component treatments in real-
life settings in an everyday patient population [22, 23]. In
addition, these multi-component treatments showed signifi-
cant and clinically relevant outcomes in symptomatic and
functional improvements and work participation up to
3 months after treatment [21]. However, it is unclear wheth-
er these positive short-term outcomes will be sustained over
time. Long-term outcomes of treatments are of special in-
terest because of the long-lasting character of fatigue com-
plaints; the perpetuating factors often lead to long-lasting
and deeply ingrained patterns [12]. Moreover, multi-
component interventions that target behavioural change, by
intervening with perpetuating factors such as dysfunctional
beliefs and coping strategies in work and private life, may
have the potential to be effective in the long term (1 year
after discharge of treatment) [24]. Therefore, we evaluated
the long-term outcomes of VR treatments in the Netherlands
in patients with prolonged fatigue complaints and participa-
tion problems. The purpose of this study is to answer the
following question: What are the outcomes up to 18 months
after VR treatment on fatigue symptoms, work participation,
work ability, daily functioning and in physiological param-




Our target population consisted of patients who enrolled in
three participating outpatient institutions for VR treatments
from 2006 to 2008. The outpatient institutions used specific
inclusion criteria to select clients before treatment, including
the following: good command of the spoken and written
Dutch, motivation to take part in the treatment, complaints
for (in general) more than 3 months and no diagnosis of a
psychiatric disorder. The inclusion criteria to participate in
this study were as follows: aged between 18 and 60 years,
fatigue complaints as a main or important symptom and
suffering from functional impairments (i.e. constraints in
everyday life) due to fatigue complaints. Eligible patients
were approached and informed about the study before they
provided written consent. This study was approved by the
medical ethical committee of the Academic Medical Center.
Design
In this practice-based research, we evaluated VR treatments
in their natural setting [22, 23] and used the TREND (Trans-
parent Reporting of Evaluations with Non-randomised
Designs) statement [25] in designing and reporting this
study. We used a pre–post-design with repeated measure-
ments at baseline (t0), upon completion of the treatment (t1)
and 3 (t′), 6 (t2), 12 (t3) and 18 (t4) months follow-up. The
study participants were recruited in two phases. First,
patients were asked to participate in the study until 6 months
after completing the treatment. After 6 months, we asked if
patients would further participate and complete question-
naires at 12 and 18 months after completion. In the current
study, we focused on the long-term outcomes (6, 12 and
18 months after completion) and report outcomes at these
follow-up measurement compared to t0 and t1. The short-
term outcomes of the VR treatments (t1 and t′ versus t0) are
described in a previous publication [21].
VR Treatments
The VR treatments were provided by three existing outpatient
institutions in the Netherlands. These institutions are focused
on patients with fatigue complaints who were on sick leave
and/or had limitations in work function. Usually patients were
referred by occupational physicians or self-referred (e.g. ad-
vised to visit the institution by people in their social environ-
ment and/or other caregivers). The main aim of the VR
treatments was to improve individual and occupational func-
tioning in patients with prolonged fatigue complaints by
achieving a normal balance between activity and rest, and
subsequently between daily life and work. From previous
research, we know that these three institutions use a
biopsychosocial-based multi-component treatment [21]. That
is, these treatments consisted of biological/physical compo-
nents, psychological/cognitive behavioural components and
social/work-directed components.
Biological/Physical Component Physical training included
an individualised progressive personal workout scheme
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based on daily heart rate levels or a graded exercise
programme using time-contingent training. Physical training
was guided by a movement specialist and/or physiotherapist
and exercises were done on a bicycle, treadmill, cross trainer
and/or power station. Physical training was aimed at im-
proving physical fitness, increasing activity levels and body
awareness. Relaxation and breathing exercises were provided
in an attempt to reduce stress and increase body awareness.
Psychological Component Group and individual sessions
with a psychologist or personal/mental coach used cognitive–
behavioural principles aimed at relieving distress, increasing
illness knowledge and raising awareness of perceptions, atti-
tudes, and beliefs. Improving coping strategies and changing
dysfunctional behaviour were goals as well.
Social/Work-Directed Component Return-to-work (RTW)
sessions (individual or group sessions) with a psychologist
or occupational expert addressed patients’ attitudes towards
work, job conditions and work adaptations, and social envi-
ronment (partner). In addition, a patient-tailored phased
RTW plan was made, in which RTW (e.g. number of work-
ing hours, work task and work demands) was gradually
increased. These sessions were intended to increase aware-
ness of behavioural patterns at work and in private life,
improve coping skills and facilitate work participation.
The VR treatments took in total 4 to 18 weeks with a visit
frequency of three to five times per week in the first part of
the treatment period (1/3) and decreased from two times in
the second part to one time per week in the third part of the
treatment period. For detailed information about the content
of the VR treatments, see Joosen et al. [21].
The specific content of the VR treatment (e.g. number of
sessions, topics focussed upon, duration of the treatment)
can differ somewhat between patients in this study because
the treatment is provided by three different institutions.
Indeed, the three institutions pursue the same goal in a
population of disabled fatigued patients using the same
approach but with a focus on the content that is tailored to
meet individual needs [21]. According to practice-based
research methodology [22, 23, 26], we aimed at evaluating
real-world practice. Therefore we decided to combine the
three treatments and report on the long-term outcomes of the
total group of patients.
Primary Outcome Measures
Primary outcome measures were degree of fatigue, work
participation, and work ability. To assess fatigue, three ques-
tionnaires were used. First, fatigue complaints were mea-
sured using the Checklist Individual Strength (CIS) [27],
which consists of 20 statements. The CIS has been validated
in the Dutch working population [28]. Second, we used the
vitality subscale of the Dutch version of the RAND-36
Health survey [29], which is almost identical to the MOS
SF-36 [30] and is a reliable and validated generic instrument
[29]. Third, work-related fatigue was measured with the
Need for Recovery After Work scale [31], with 11 yes/no
items. The Need for Recovery scale was found reliable and
valid in a working population [32, 33].
Data on work participation were collected by researcher-
formulated questions at different measurement times. Data
consisted of the following: (1) current work status, in terms
of employed or unemployed; (2) number of contractual
working hours; and (3) absolute number of hours the patient
was working at that moment. With these data we determined
the following: (1) percentage of return to original work,
defined as the mean percentage of return working to the
original contracted working hours at t0, and (2) percentage
of return to work, defined as the mean percentage of return
working to the contracted working hours at the measure-
ment time [34]. In this latter variable, changes in contracted
working hours during the study period were taken in
account.
Self-reported work ability was assessed using two items
from the Work Ability Index [35]: (1) currently perceived
work ability compared with lifetime best, scoring between 0
(‘not being able to work’) and 10 (‘lifetime best work
ability’), and (2) personal prognosis of work ability in the
next 2 years, scored on a three-point scale (‘hardly able to
work’, ‘not sure’ and ‘fairly sure to be able to work’).
Secondary Outcome Measures
The secondary outcome measures included physical func-
tioning, mental health, social functioning and heart rate
variability (HRV). Subscales of the RAND-36 Health sur-
vey [29] were used to measure physical functioning and
physical role limitation, mental health and emotional role
limitation, and social functioning.
HRV was used as a physiological indicator that reflects
sympathetic and parasympathetic activity of the autonomic
nervous system. Prolonged exposure to stress can lead to
dysregulation of this system (i.e. lower parasympathetic
activity) [14, 36] and can be identified by decreased HRV
[37, 38]. HRV was recorded using the Co2ntrol (Decon
Medical Systems, Weesp, the Netherlands), a small device
attached to a chest strap that detects beat-to-beat intervals
[39]. Due to practical constraints, HRV was only measured
at t0, t1 and t2 during a standardised test protocol: 5 min
seated in a resting position for adaptation, followed by 12 min
light exercise on a bicycle ergometer using a single load of
50 W with a pedal frequency between 60 and 65 min−1. The
Co2ntrol was developed according to the guidelines of the
European and North American Task Force [40]. It was
found to provide reproducible HRV measurements in
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healthy individuals [41] and in patients with prolonged
fatigue [42].
In addition, personal demographics, duration of fatigue
symptoms and duration of functional impairments were
obtained by questionnaires before treatment (patient character-
istics at baseline). Furthermore, additional treatments and sick
leave duration were recorded at two points in time (t3 and t4).
At follow-up, patients were asked to report which health care
providers they had visited concerning fatigue complaints dur-
ing the last 6 months to monitor additional treatments. Next,
sick leave duration during the last 6 months was recorded.
Data Reduction
Data from the questionnaires were reduced and/or trans-
formed into total scores. In CIS data, we added the item
scores to a total score ranging from 20 to 140. Higher scores
indicated a higher severity of fatigue. Item scores from the
Need for Recovery scale were added and transformed [29]
into a scale ranging from 0 to 100. Higher scores indicated a
higher degree of need for recovery after work. RAND-36
scores were added separate per scale and transformed [29]
into a score ranging from 0 to 100; higher scores represent
better outcomes.
To define HRV, raw data were transferred to HRVAnalysis
Software version 2.0 (http://venda.uku.fi/research/biosignal)
and data artefacts were detected and processed by the soft-
ware. The data were de-trended using the smoothn prior
option. To determine the spectrum of HRV, the fast Fourier
transform option was used and data were re-sampled at a
rate of 4 Hz using cubic interpolation. The final 9 min of the
12-min recording period during light exercise were selected.
HRV was measured by means of heart period high-
frequency (HF) power. HF power values were used to esti-
mate respiratory sinus arrhythmia (RSA), the variability of
heart period in the respiratory frequency band. RSA is
considered a valid index of changes in cardiac vagal tone,
which interacts with parasympathetic activity [38, 43]. In
this study, HF power was computed in the 0.15–0.5-Hz
respiration window. The VR treatments were expected to
have beneficial effects on physiological status (i.e. raise HF
power after completion of the interventions).
Statistical Analysis
Our target sample size was 110 patients from the first phase
of the evaluation study [21]. Because we knew that part of
this sample dropped out of the study after the first phase, we
performed a non-response analysis to check for possible
bias. Differences in baseline characteristics and primary
short-term outcomes (i.e. degree of fatigue and return to
work) were tested with t tests for continuous variables and
chi-tests for categorical variables.
To analyse the long-term outcomes of the variables over
time up to 18 months, we performed linear mixed model
analyses based on repeated measures. The best fitting co-
variance–variance model was tested before the analysis was
applied. If a statistically significant overall effect was found,
post hoc tests using Bonferroni correction (taking into ac-
count the multiple comparisons) were performed to compare
outcomes between follow-up measurements and t0 and t1.
To assess the changes in HRV between t0 and t1 and
between t0 and t2, non-parametric Wilcoxon signed rank
tests were carried out. Statistical analyses were performed
using SPSS version 16.0 for Windows (SPSS Inc., Chicago,
IL, USA). Values of p<0.05 were considered statistically
significant. Post hoc values in primary and secondary out-
come measures were considered significant at p<0.0083
due to Bonferroni corrections (p value divided by the num-
ber of comparisons, i.e. six).
Results
Patient Characteristics
A total of 110 patients, 50 men and 60 women, enrolled in
this study and 60 patients completed the 18-month follow-
up measurement (Fig. 1). Reasons for failure to follow-up
are presented in Fig. 2. Only ‘completers’, 60 patients (28
men and 32 women) who completed the 18-month follow-
up measurement, were included in the analysis. Patients had,
on average, severe disabling fatigue complaints for many
years (mean 3.4 years). Most patients (73%) were partly or
fully on sick leave, 17% were working full time and 10%
had no paid job (Table 1).
We performed a non-response analysis and compared
‘completers’ with ‘non-completers’. No significant between
group difference was found on gender, age, duration of
fatigue complaints, duration of functional impairments and
fatigue severity at baseline. ‘Completers’ and ‘non-com-
pleters’ did not differ in fatigue severity levels (i.e. mean
CIS scores) between t1 and t0, nor did the groups differ in
return-to-original work percentage between t1 and t0.
Half of the 60 patients (52%) volunteered to participate in
various additional treatments between 6 and 18 months after
completing the VR treatments. Many of these patients (21–
23%) were treated by general practitioners and medical
specialists or took extra sessions in the VR institution.
However, most patients (61%) sought care in the comple-
mentary and alternative medicine field (including acupunc-
ture, homeopathy and orthomolecular medicine). Type and
number of additional treatments are reported in Table 2.
In the period between 6 and 18 months after treatment, 17
patients (28%) had not been on sick leave for 1 year. In this
period, 14 patients (24%) had been on sick leave due to
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fatigue complaints. The mean duration of sick leave was
9 weeks, ranging from 2 days to 1 year. Two patients were
on sick leave for the full 1-year period (data not shown).
Primary Outcome Measures
Figure 2 shows the results (mean scores, confidence inter-
vals and p values) of primary outcomes. Fatigue severity,
work-related fatigue, vitality, percentage of return to original
work, percentage of return to work and perceived work
ability all improved significantly (p<0.001) over time. In
post hoc analyses, all outcomes improved significantly (p<
0.001) in follow-up measures compared to baseline. In
addition, the percentage of cases with chronic fatigue (CIS
score above 76) [44] decreased from 87% at baseline to 46%
after treatment and to 37% at 18 months follow-up.
Fig. 1 Flow chart of patients
through the study
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Compared to t1, long-term improvements were less clear.
No relapse in the assessed outcomes was found at 6, 12 and
18 months after treatment compared to t1. Moreover, two
out of three fatigue outcomes significantly improved at
6 months after treatment (t2) compared to t1 [work-related
fatigue (p00.002) and vitality (p00.004)], as did work
ability (p<0.001). In addition, both work participation
long-term improvements (t2, t3 and t4) were significant
(p<0.001) compared to t1.
Out of 60 patients, 28 (47%) stated at baseline that they
were ‘fairly sure’ they would be able to work in 2 years. At
t1, this number rose to 44 patients (73%). At 12 and
18 months follow-up, 39 out of 53 patients (74%) and 44
out of 58 patients (76%), respectively, were ‘fairly sure’ they
would be able to work in 2 years (data not shown).
Secondary Outcome Measures
Table 3 reports mean scores, confidence intervals and over-
all p values in the secondary outcomes per measurement.
Five secondary outcomes (physical functioning, physical
role limitation, mental health, emotional role limitation and
social functioning) improved significantly (p<0.001) over
time. These outcomes improved significantly (p<0.001) at
all follow-up measures compared to baseline.
In post hoc analyses compared to t1, non-significant
long-term improvements at t2, t3 and t4 were found in
physical functioning (p00.470, p00.239 and p00.396, re-
spectively) and physical role functioning (p00.012, p0
0.035 and p00.041, respectively). In mental health, mean
scores at 6 months after treatment improved significantly
Fig. 2 Primary outcomes: fatigue severity, work-related fatigue, vital-
ity return to original work, return to work and work ability. Mean
scores (95% confidence intervals) on primary outcomes at t0 (base-
line), t1 (at completion of the treatment), t2 (6 months follow-up), t3
(12 months follow-up) and t4 (18 months follow-up) and p values for
the differences between follow-up measures and t1. *p<0.001, signif-
icant post hoc outcome within subjects compared with t0. Significant
when p<0.0083 (Bonferroni corrected). ^p<0.0083, significant post
hoc outcome within subjects compared with t1 (p<0.0083 Bonferroni
corrected)
Table 1 Patients’ characteristics
Mean (SD) or frequency (%)




Severe fatigue (CIS score >76)a
(percentage)
87%
Duration of fatigue complaints in years 4.6 (5.1)
Duration functional impairments in years 3.4 (4.4)
Employment status
Paid job, fully at work 10 (17%)
Paid job, partly on sick leave 24 (40%)
Paid job, fully on sick leave 20 (33%)
No paid job 6 (10%)
a Bültmann et al. [44]
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(p<0.001) and emotional role limitation improved signifi-
cantly 6 (p00.003) and 12 months (p00.004) after treatment
compared to t1. Social functioning increased significantly as
well after the treatment was stopped (p00.003 at 6 months
follow-up compared to t1).
For heart rate variability, compared with baseline, HF
power values improved significantly (p<0.001) after treat-
ment and at 6 months follow-up (p00.049). However, HF
power did not improve significantly at 6-month follow-up
compared with t1 (p00.119, Table 4).
Table 2 Additional treatments.
Type and number (percentage)
of additional treatments between
6 and 18 months follow-up
aNumber of patients (in percent)
receiving additional treatment
6–18 months. More than one




Type of treatment n (%)a
VR treatment Extra sessions, e.g. physical training, physical therapy,
mental coach, psychologist, advice
13 (42)
General practitioner 13 (42)
Occupational physician 7 (21)
Medical specialist Internist (2); neurosurgeon (3), rheumatologist (2);
lung specialist (1); ear, nose and throat specialist (1);
specialist in metabolic diseases (1); psychiatrist (1);




Vocational rehabilitation counsellor 1 (3)
Career counsellor 2 (6)
Complementary and alternative
medicine
Whole medical systems: homeopathy (2), naturopathic
medicine (2)
4 (13)
Biological based practices: orthomolecular medicine (1) 1 (3)
Mind–body medicine: healing (1), paranormal medicine (1) 2 (6)
Manipulative and body-based practices: haptonomy (1),
osteopathic (1), Bowen therapy (2), acupuncture (4),
bio-energetic therapy (1)
9 (29)
Energy therapies: kinesiology (2), prognos therapy (1),
bio-resonance therapy
3 (10)
Others Nutrition: B12 insufficiency therapy (1) 1 (3)
Sleeping clinic (1), coach (1), Mensendieck therapy (1),
course: personal development (1)
4 (13)
Table 3 Secondary outcomes: physical functioning, mental health and social functioning











0–100 0–100 0–100 0–100 0–100
n 60 60 60 60 60
t0 M (95% CI) 69 (62.9–74.1) 13 (5.9–20.8) 53 (48.5–58.2) 41 (30.0–52.3) 49 (41.9–55.6)
t1 M (95% CI) 85 (80.4–90.2)* 54 (43.1–65.3)* 69 (64.2–73.0)* 67 (56.2–77.2)* 68 (62.0–74.3)*
t2 M (95% CI) 86 (81.4–91.3)* 68 (58.1–78.6)*, ** 76 (72.1–79.4)*, ** 83 (74.2–91.4)*, ** 76 (69.2–82.0)*, **
t3 M (95% CI) 88 (82.7–92.7)* 67 (57.0–78.0)*, *** 73 (68.3–77.1)* 85 (76.8–93.1)*, ** 74 (67.3–81.4)*
t4 M (95% CI) 87 (82.4–92.0)* 68 (57.1–78.8)*, *** 75 (70.2–79.3)*, *** 82 (71.9–91.3)*, *** 77 (70.0–83.3)*, ***
Overall p value <0.001 <0.001 <0.001 <0.001 <0.001
Mean scores (95% confidence Intervals) on physical functioning, mental health, social functioning at t0 (baseline), t1 (at completion of the
treatment), t2 (6 months follow-up), t3 (12 months follow-up) and t4 (18 months follow-up) and p values for the differences over the five
measurements
*p<0.001: post hoc outcome within subjects compared with t0, significant when p<0.0083 (Bonferroni corrected); **p<0.0083: post hoc outcome
within subjects compared with t1, significant when p<.0083 (Bonferroni corrected); ***p<0.05: post hoc outcome within subjects compared with
t1, significant when p<0.0083 (Bonferroni corrected)
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Discussion
The results of our study suggest that in patients with pro-
longed fatigue, multi-component VR treatments significantly
decrease fatigue symptoms and improve work participation,
work ability, and physical, mental, and social functioning
over the long term. In addition, HRV as a physiological
parameter did improve 6 months after the VR treatments.
The results show that the positive changes in patients mea-
sured immediately after completing the treatment were main-
tained over the long term. Moreover, positive changes for
fatigue complaints, work participation, work ability, mental
health and social functioning improved further up to
18 months after treatment.
Not surprisingly, the largest improvements compared to
baseline were found immediately after completing the VR
treatment. More surprisingly, the results show that short-
term improvements are maintained over the long term, after
treatment was stopped. These long-term improvements can
be interpreted as clinically relevant outcomes, that is
Cohen’s effect size statistic d>0.50 [45], due to large effect
sizes (d>1.2) in all outcome measurements. First, the three
fatigue measures show the same pattern of recovery. More-
over, mean fatigue severity scores (CIS) and mean scores in
work-related fatigue decreased below the cut-off points of
these scales, indicating chronic fatigue (mean076) [44] and
high risk of receiving treatment (mean055), respectively
[46, 47]. Despite these significant and clinically relevant
results, after 18 months patients in this study reported still
more fatigue complaints than the Dutch (working) popula-
tion (mean CIS score047 and vitality score069) [44, 48].
Second, both work participation measures improved further
after treatment. Eighteen months after completing the treat-
ment, return to original work rose to 87%. That means that
on average, patients worked for 87% of their contract hours
at baseline. This result is similar to studies reporting RTW
after multi-component treatment in upper extremity com-
plaints [34] and in previous retrospective data [49]. Taking
into account that some patients (n015) modified their em-
ployment contract (i.e. less contracted hours) during the
study period, return to work rose to 98% at 18 months
follow-up. The VR treatment was aimed at facilitating full
RTW by using work-directed components. However, anoth-
er important aim of the treatment was to increase awareness
of attitudes towards work and improve coping strategies and
behaviour. In addition, patients have indicated that their
work participation increases by learning to recognise their
behavioural patterns at work and in private lives, and train-
ing to cope with their limitations and capacities (e.g. setting
boundaries) [50]. As a result of gaining this insight, patients
may have changed their employment contract to avoid ex-
ceeding their capacities, thus resulting in a higher return-to-
work percentage. It should be noted that eight patients were
not included in the return-to-work analysis because they had
no paid job anymore at 18 months follow-up. Because we
do not know why these patients lost their employment
contract (e.g. retirement, going back to college, permanent
work disability) and if this job loss was the result of attending
the VR treatment, we cannot draw conclusions from this.
The secondary outcomes, physical functioning, men-
tal health and social functioning, showed long-term
improvements. Physical functioning mean scores at
18 months follow-up were higher than scores in the
Dutch population (mean083) [48]. Mental health and
social functioning improved significantly after the treatment
was stopped. Eighteen months after treatment, mental health
scores moved towards the scores found in the Dutch popu-
lation (mean077) [48], but social functioning scores stayed
below the scores of the Dutch population (mean084). As for
HRV, we found 6-month follow-up (t2) improvements com-
pared with baseline. Mean HF power worsened compared
with t1, however not significantly. Few, if any, studies have
investigated the effects of vocational interventions on HRV
in fatigued patients. Though, we do know that physical
exercise that is focussed on physiological adaptation
improves HF power in other populations (e.g. healthy and
coronary patients) over the short term [51, 52]. However,
these effects may be maintained only if the exercise is
continued. We do not know if the patients in our study
continued physical training in their private time.
The main aim of the VR treatments was to improve
individual and occupational functioning by achieving a nor-
mal balance between activity and rest, and subsequently
between daily life and work. To achieve this normal balance,
perpetuating factors that hindered recovery were addressed
from a biopsychosocial perspective. The complexity of the
treatment and outcomes, that is a combination of body
awareness, increased physical fitness, awareness of attitudes
and beliefs towards work and in private life, improving
coping strategies and making a gradual RTW plan, is
thought to increase daily functioning and, moreover, change
patients’ behaviour (e.g. adopt a new lifestyle). Consequent-
ly, this would improve participation over the long term. The
current results show that although fatigue symptoms remain
prevalent, outcomes on functioning in daily life and work
Table 4 Heart rate variability
t0 t1 t2
N 58 37 55
HF power (m s2), SD 50 (64.4) 126 (246.7)* 75 (126.0)**
Mean scores (standard deviations) on HF power. Comparisons were
made between t1–t0, t2–t0 and t2–t1
*p00.001 Wilcoxon signed rank test (t1 compared with t0); **p0
0.049 Wilcoxon signed rank test (t2 compared with t0)
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participation improve over the long term and improve fur-
ther after treatment is stopped. This suggests that patients
are better capable of coping with perceived complaints in
their private and working lives. These findings are sup-
ported by the findings of patients’ RTW experiences after
treatment in this same population (Joosen et al., submitted).
In addition, in upper extremity musculoskeletal disorders
[34] and in low back pain [53], biopsychosocial rehabilita-
tion showed positive effects on work participation over the
long term (1 year follow-up).
This study was designed as a practice-based research
attempting to answer a question that originates from every-
day practice. In the Netherlands, outpatient VR care is
decontrolled. Thus, various treatments are designed by out-
patient institutions and carried out by experienced trainers,
caregivers and supervisors. It is of great importance to
evaluate the outcomes of these everyday practices, as many
fatigued patients who seek help attend these treatments.
However, conducting a randomised controlled study in this
setting was not feasible; among other reasons, institutions
were bound by contracts with employers. In practice-based
research, the content of the intervention and patients partic-
ipating in the study should be the same as in “clinical”
practice. Next, a broad range of real-life outcomes should
be collected. These factors were taken into account, which
gives this study high external validity [22, 26, 54]. Due to
the absence of a control group, which is not unusual in
practice-based research, a number of measures were taken
to strengthen the design (and thereby internal validity)
according to the TREND statement [25]. The content of
VR treatment was theoretically specified, outcomes were
selected based on the interventions, and measured using
reliable and validated outcome variables. The results of this
study are in line with and confirmed by different perspec-
tives by longitudinal data (current study), process evaluation
(described in [21]) and patients’ perspectives [50]. In addi-
tion, considering the long-standing nature of fatigue com-
plaints and perceived disabilities, spontaneous recovery of
these problems was unlikely. Considering these points, we
believe that the outcomes of this study may be attributed to
the VR treatment provided by the outpatient institutions in a
population of prolonged fatigue patients with participation
problems. It would, however, be interesting to repeat this
study in a population of workers specifically diagnosed with
CFS.
We conclude that multi-component VR treatments have
the potential to reduce fatigue symptoms and improve indi-
vidual functioning and work participation in patients with
severe prolonged fatigue complaints over the long term
without relapses. It is therefore recommended to use multi-
component VR treatments with a biopsychosocial approach
for patients with disabling prolonged fatigue complaints.
These results are of importance to the occupational health
field in preventing and managing sickness absence in fa-
tigued workers through referral to VR treatments.
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